Figure 3
![Figure 3. Relapse-free survival and OS from CR according to the new risk classification of Beldjord et al. (A) Relapse-free survival in T-ALL patients (86% vs 52% at 5 years; hazard ratio [HR], 4.20; 95% CI, 1.85-9.51; P = .001). (B) OS from CR in T-ALL patients (91% vs 62% at 5 years; HR, 4.14; 95% CI, 1.58-10.83; P = .004). High risk includes MRD-positive and or adverse genetics including no NOTCH1/FBXW7 mutation or presence of N/K-RAS mutation and/or PTEN gene alteration.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/126/7/10.1182_blood-2014-10-551895/4/833f3.jpeg?Expires=1738129020&Signature=Yj2HBJzXVyukUTQhnGlJW8FALJtrYjoDzkqC1TKYRlzOjvCIwwA8eqmfz3kCOHcXGldwo92QnKTOzVSVGOqZRNvZKW7frHHYG83DV~HEcokW~ueaOdDnszP3s1xlsfsquGf6KRkiEMDoVEgXCdI5Qx5Dvfg7SmJmNhGT-7dnSCsOFAKHNv5kJU9YZLGfuDIEy8XKzZmqEi1z7Hp7wAo8~CVJmvQEW6shUVmaVFeqzhoqlRhDPSrorOM-xgNGBxL6b25i6l~YmHoCw20Zm366sHVkQ4y6RJqoylKj1tgWSH7t9d~98BZ6XA-QgbV4uI-A04g5JtiuqwtqMA4XY7MV-g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Relapse-free survival and OS from CR according to the new risk classification of Beldjord et al. (A) Relapse-free survival in T-ALL patients (86% vs 52% at 5 years; hazard ratio [HR], 4.20; 95% CI, 1.85-9.51; P = .001). (B) OS from CR in T-ALL patients (91% vs 62% at 5 years; HR, 4.14; 95% CI, 1.58-10.83; P = .004). High risk includes MRD-positive and or adverse genetics including no NOTCH1/FBXW7 mutation or presence of N/K-RAS mutation and/or PTEN gene alteration.
